Owc Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
(a) On April 4, 2019, OWC Pharmaceutical Research Corp. (the “Company”) held a special meeting of the stockholders of the Company (the “Special Meeting”) at the offices of the Company’s counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (“Mintz Levin”), 666 3rd Avenue, New York, New York 10017.
(b) Of the 165,152,579 shares of the Company’s common stock entitled to vote at the Special Meeting, 140,646,588 shares were represented at the meeting in person or by proxy, constituting a quorum. The voting results for the only matter submitted to vote at the Special Meeting are as set forth below. This proposal is described in further detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on February 26, 2019.
The stockholders approved a proposal authorizing the adjournment of the Special Meeting, if a quorum was present, to solicit additional proxies if there were insufficient votes to approve the proposal regarding the reverse stock split.
| Votes For | Votes Against | Votes Abstained | Broker Non-Votes |
| 76,456,213 | 61,219,334 | 2,971,041 |
In connection with stockholder approval of the adjournment proposal described above, the Company elected to adjourn the Special Meeting until April 18, 2019 at 10:00 a.m., local time, to be held again at the offices of Mintz Levin, 666 3rd Avenue, New York, New York 10017. The record date for the Special Meeting remains February 6, 2019.
About Owc Pharmaceutical Research Corp. (OTCMKTS:OWCP)
OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.